Suppr超能文献

[组织型纤溶酶原激活剂(t-PA)给药期间的类过敏反应]

[Anaphylactoid reaction during administration of tissue plasminogen activator (t-PA)].

作者信息

Cannas S, De Leo A, Marzari A

机构信息

Cattedra di Cardiologia, Università degli Studi, Padova.

出版信息

G Ital Cardiol. 1997 Mar;27(3):278-80.

PMID:9244730
Abstract

The use of tissue plasminogen activator (t-PA) in the management of acute myocardial infarction, as effective thrombolytic agent, is well established. Thrombolytic therapy, limiting the extent of myocardial necrosis, reduces the infarct-related morbidity and mortality and improves the prognosis in patients with acute myocardial infarction. Thrombolytic agents present various side effects. Allergic reactions may occur with both streptokinase (ST) (or with anistreplase, the equimolecular mixture of streptokinase and human plasminogen); and t-PA. The incidence of allergic reactions associated with the use of t-PA is much lower if compared with other thrombolytic agents. Since t-PA is structurally identical to endogenous t-PA, its administration should not cause anaphylactic reactions. The purpose of this case presentation is to describe the occurrence of an anaphylactoid reaction during infusion of t-PA in a 63 year-old man, admitted to the Cardiac Care Unit (C.C.U.) with diagnosis of acute myocardial infarction.

摘要

组织型纤溶酶原激活剂(t-PA)作为有效的溶栓剂用于急性心肌梗死的治疗已得到充分证实。溶栓治疗可限制心肌坏死范围,降低急性心肌梗死患者的梗死相关发病率和死亡率,并改善预后。溶栓剂存在各种副作用。链激酶(ST)(或茴香酰化纤溶酶原链激酶激活剂复合物,即链激酶与人纤溶酶原的等分子混合物)和t-PA都可能发生过敏反应。与其他溶栓剂相比,使用t-PA相关的过敏反应发生率要低得多。由于t-PA在结构上与内源性t-PA相同,其给药不应引起过敏反应。本病例报告的目的是描述一名63岁男性在输注t-PA期间发生类过敏反应的情况,该患者因诊断为急性心肌梗死入住心脏监护病房(CCU)。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验